NanoString Technologies Inc to Discuss the Efficacy of CAR-T Cell Therapy for LBCL Transcript

May 11, 2022 / 03:00PM GMT
Elizabeth Schneider - NanoString Technologies, Inc. - Senior Global Marketing Manager

Hello, everyone. Welcome to another NanoString Webinar Presentation on Oncology Research. My name is Elizabeth Schneider, Senior Global Marketing Manager here at NanoString. Today, we have the pleasure of speaking Dr. Alexandre Hirayama. He is a Research Associate in the Clinical Research Division at Fred Hutchinson Cancer Research Center. And his presentation today is going to be on understanding the efficacy of CAR-T cell therapy for large B-cell lymphoma.

A little bit about Alexandre. He is an acting instructor in the Department of Medicine at the University of Washington School of Medicine and an attending physician of the Seattle Cancer Care Alliance. He joined Fred Hutch in July of 2017 to train as a physician scientist in the clinical research division laboratory of Dr. Cameron Turtle and he has worked on elucidating factors impacting outcomes of CD19-targeted CAR-T cell therapy for adults with B-cell malignancies.

We will be having a Q&A at the end of the session. For those of you who are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot